111: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén - Part 1

In this episode, we explore the delicate dance between artificial intelligence and biological research with Lars Brandén, Director of Biology at Kolibri. From his early fascination with gene therapy to pioneering high-throughput screening centers at prestigious institutions, Lars shares invaluable insights on bridging the gap between academic innovation and industrial application.What sets this conversation apart is Lars' compelling perspective on why the popular "agile development" model doesn't always translate smoothly to bioprocess development – and why that matters for the future of drug development. His journey from the Karolinska Institute to leading cutting-edge biological research offers a unique lens on the evolution of biotech.Key takeaways for listeners:Learn why scientists must develop broader cross-disciplinary knowledge to effectively leverage AI tools in researchDiscover how AI could dramatically reduce drug development timelines and costs within the next five yearsUnderstand the potential for AI to democratize access to cell and gene therapies through optimized production methodsJoin us for this fascinating exploration of how domain expertise and artificial intelligence can work in harmony to accelerate breakthrough therapies. Whether you're a biotech professional or simply curious about the future of medicine, this episode offers valuable insights into the transformation of drug development in the AI era.Listen now to discover how the intersection of human expertise and artificial intelligence is reshaping the future of personalized medicine.Connect with Lars Brandén:LinkedIn: https://www.linkedin.com/in/larsbrandenNext Steps:Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at [email protected] the show